Edward Tenthoff
Stock Analyst at Piper Sandler
(0)
# 4398
Out of 5,291 analysts
227
Total ratings
33.96%
Success rate
-13.31%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Century Therapeutics | Maintains: Overweight | 4 2 | 0.52 | 284.62% | 8 | Mar 20, 2025 | |
Dyne Therapeutics | Maintains: Overweight | 53 48 | 11.46 | 318.85% | 6 | Feb 28, 2025 | |
Mesoblast | Reiterates: Overweight | 15 24 | 12.12 | 98.02% | 5 | Feb 7, 2025 | |
Legend Biotech | Reiterates: Overweight | 78 78 | 35.13 | 122.03% | 4 | Dec 30, 2024 | |
Xencor | Upgrades: Overweight | 20 30 | 11.21 | 167.62% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 45 | 13.8 | 226.09% | 10 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 296 296 | 268.5 | 10.24% | 7 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 115 69 | 31.12 | 121.72% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 4 | n/a | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 1 | 0.82 | 21.95% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 5 | 0.78 | 541.03% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 4.26 | 322.54% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 35 | 11.45 | 205.68% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 11 11 | 0.73 | 1406.85% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 20 20 | n/a | n/a | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 3 | 1.71 | 75.44% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 13 5 | 0.03 | 16566.67% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 3 | 0.91 | 229.67% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 16 16 | 5.09 | 214.34% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 105 105 | 36.99 | 183.86% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 4 6 | 0.84 | 614.29% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 150 150 | 3.31 | 4431.72% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 120 80 | n/a | n/a | 5 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 5 | 0.88 | 468.18% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 15 | 3.01 | 398.34% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 56 | 29.58 | 89.32% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 8 10 | n/a | n/a | 3 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 5 2 | n/a | n/a | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 13 | n/a | n/a | 2 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 70 55 | 7.61 | 622.73% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 7 | n/a | n/a | 2 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 31 | 1.21 | 2461.98% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 1 | 0.03 | 1566.67% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 20 | n/a | n/a | 5 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 5 | n/a | n/a | 3 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 3 | 0.26 | 1053.85% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 6 2 | n/a | n/a | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 6 | 0.5 | 1100% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 9 | 0.74 | 1116.22% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 37 44 | 19.34 | 127.51% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 160 60 | n/a | n/a | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 76 37 | 8.99 | 311.57% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 100 | n/a | n/a | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 112332 32560 | 1.15 | 2831204.35% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 250 354 | 588.92 | -39.89% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 135 | 1.28 | 10446.88% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 261 323 | 492.19 | -34.37% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 80 25 | n/a | n/a | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 33 36 | 36.7 | -1.91% | 2 | Feb 16, 2021 |